Comprehensive Study Guide on Prostaglandin Analogs for Glaucoma

Overview of Prostaglandin Analogs

• Prostaglandin analogs represent the most popular class of medications for the treatment of glaucoma.
• They are considered the most effective pharmacological intervention for lowering intraocular pressure ($IOP$).
• Dosing frequency is minimal, typically required only once per day.
• In general, these medications are very well tolerated by patients.

Mechanism of Action and Efficacy

• Mechanism of Action: While the precise biochemical mechanism is not fully understood, it is established that these agents increase uveoscleral outflow, also referred to as non-conventional outflow.
  • They facilitate the flow of aqueous humor through the face of the ciliary body.
  • Fluid is ultimately directed into the suprachoroidal space.
• Efficacy in Pressure Reduction: Prostaglandin analogs decrease intraocular pressure by approximately $25\%$ to $30\%$.
• Currently, there is no single topical agent that outperforms prostaglandin analogs in terms of pressure-lowering capacity.

Clinical Indications and Limitations

• Primary Indications: Use is indicated for all forms of open-angle glaucoma.
• Limitations in Specific Glaucoma Types:
  • Primary Congenital Glaucoma: These agents are not tremendously effective in this population.
  • Angle-Closure Glaucoma: They are less effective because the iris mechanically obstructs both the trabecular meshwork and the ciliary body face, preventing the medication from facilitating outflow.
• Inflammatory Glaucoma: There have been historical concerns regarding the use of these analogs in inflammatory glaucoma; however, clinical observation suggests that many patients with inflammatory glaucoma do quite well on these medications.
• Cystoid Macular Edema (CME) Risk: These medications are associated with the development of cystoid macular edema, particularly in patients who are aphakic or pseudophakic. Consequently, these individuals may not be ideal candidates for this therapy.

Ocular and Periocular Side Effects

• Iris Pigmentation:
  • Occurs in up to $1/3$ ($33.3\%$) of patients.
  • This change is most frequently observed in eyes with hazel or green-brown irises.
  • It is rarely seen in dark brown irises (which are already fully pigmented) or very light blue eyes.
• Periocular Skin Pigmentation: Darkening of the skin around the eyes may occur.
• Cellular Mechanism of Pigmentation: Both iris and skin pigmentation changes are caused by an increase in the number of melanosomes within the melanocytes.
  • Crucially, there is no increase in the actual number of melanocytes (no cellular proliferation).
  • There is currently no evidence indicating an increased risk of developing melanoma or other pigmentary tumors.
• Hypertrichosis (Lash Growth):
  • The development of long lashes is very common.
  • Lashes can sometimes become unusual in appearance or unattractive.
  • This side effect is highly obvious in patients using the medication unilaterally (in only one eye).
  • Some patients choose to apply the medication to the fellow (healthy) eye purely to maintain symmetry in eyelash appearance and length.
• Prostaglandin-Associated Periorbital Orbitopathy (PAP):
  • Characterized by a deep-set eye and a high, deep furrow above the upper eyelid.
  • This condition is often more apparent in unilateral users.
  • Reversibility: Unlike lash changes or iris pigmentation, PAP is reversible upon discontinuation of the drug.
  • Clinical Case Example: A young woman involved in an auto accident developed glaucoma in her left eye. She experienced PAP and long lashes on that side, initially attributing the deep orbital furrow to her trauma. After a drainage tube was implanted and the prostaglandin analog was discontinued, the orbitopathy resolved completely.
• Other Side Effects:
  • Reactivation of herpes keratitis.
  • Promotion of cystoid macular edema in susceptible (aphakic/pseudophakic) eyes.

Comparison of Specific Pharmaceutical Agents

There are four primary forms of prostaglandin analogs available in the United States:

• Latanoprost (Xalatan):
  • The first prostaglandin analog introduced.
  • Generally considered slightly less effective than Bimatoprost but typically presents with fewer side effects.
• Bimatoprost (Lumigan):
  • Considered very effective, potentially more so than Latanoprost, though it may have a higher side-effect profile.
• Travoprost (Travatan Z):
  • Clinical efficacy and profile are almost identical to Latanoprost.
  • It utilizes a different preservative system, which is beneficial for patients with sensitivities or allergies to benzalkonium chloride ($BAK$).
• Tafluprost (Zioptan):
  • Notable for being a preservative-free formulation of a prostaglandin analog.

Clinical Dosing and Administration

• Timing: These medications are typically administered at night (in the evening).
• Dosing Frequency Warning: Using these agents more than once per day results in a paradoxical effect where the intraocular pressure actually increases.
• There is no therapeutic advantage to twice-daily dosing.
• These remain the most potent agents available for routine pressure reduction and are usually the first-line choice for most glaucoma patients.